Ser374
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser374  -  HDAC3 (human)

Site Information
KMLNHAPsVQIHDVP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1874020216

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mutation of modification site ( 1 )
Disease tissue studied:
leukemia ( 1 ) , acute myelogenous leukemia ( 1 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 1 ) , macrophage ( 1 ) , macrophage-bone marrow ( 1 ) , RAW 264.7 (macrophage) ( 1 ) , THP1 (myeloid) ( 1 )

Upstream Regulation
Putative in vivo kinases:
HIPK2 (human) ( 1 )
Treatments:
LPS ( 1 ) , purvalanol ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on HDAC3:
acetylation ( 1 ) , enzymatic activity, inhibited ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, inhibited ( 1 )
Inhibit interaction with:
DAD1 (human) ( 1 )

References 

1

Zhang F, et al. (2021) HIPK2 phosphorylates HDAC3 for NF-κB acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis. Proc Natl Acad Sci U S A 118
34244427   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.